Covid-19 in Italy, the prescriptions of monoclonal antibodies. In the last seven days, monitored by the Italian Medicines Agency Aifa, from 27 August to 2 September, they were 564 against 505 the previous week (+ 11.7%), for a grand total of 8,434 as of March 10, when these medicines have been authorized as an emergency in Italy for particularly frail people with recent Sars-CoV-2 infection and without severe symptoms. 199 structures from 21 regions or autonomous provinces have prescribed these therapies. This is what emerges from the 22nd Aifa report on the monitoring of these drugs.
The daily average of prescriptions in the period examined was 96 against 72.14 in the previous week. To date, the majority of treated patients (3,887) have received the combination of the two antibodies bamlanivimab and etesevimab, followed by the mix casirivimab-imdevimab (3,724), as the last bamlanivimab alone (823).
From the start of monitoring, in absolute numbers Lazio remains the region with the greatest use with 1,209 patients treated, followed by Veneto with 1,167 patients and Tuscany with 1,123, while in the last places there are Molise and the Autonomous Province of Bolzano, respectively stopped. at 14 and 3 patients entered in the register. In the last week analyzed, the highest number of prescriptions was reported by Tuscany (112, + 28.7% compared to the previous week), followed by Veneto (109, + 17.2%), Sicily (72, + 26.3%) and Lazio (58, + 1.8% compared to the previous week).